Factors Affecting the Adverse Drug Reactions of Mycophenolate Mofetil |
Kim, Keum-Hi
(Department of Pharmacy, Seoul National University Hospital)
Lee, Ju-Yeun (Department of Pharmacy, Seoul National University Hospital) Park, Kyung-Ho (Department of Pharmacy, Seoul National University Hospital) Son, In-Ja (Department of Pharmacy, Seoul National University Hospital) Lee, Hye-Suk (Department of Pharmacy, Seoul National University Hospital) |
1 | Kuypers DR, de Jonge H, Naesens M, et al., Current target ranges of mycophenolic acid exposure and drugrelated adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther. 2008 Apr; 30(4): 673-683. DOI ScienceOn |
2 | The US Renal Transplant Mycophenolate Mofetil Study Group. Sollinger HW. : Mycophenolate mofetil for the prevention of acute rejection in cadaveric renal allograft recipients. Transplantation. 1995;60:225-232. DOI ScienceOn |
3 | Mourad M, Malaise J, Chaib Eddour D, et al., Correlation of mycophenolic acid pharmacokinetic parameters withside effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001; 47: 188-94. |
4 | Shaw LM, Figurski M, Milone MC, et al., Therapeutic drug monitoring of mycophenolic acid. Clin J Am Soc Nephrol. 2007 Sep; 2(5): 1062-1072. DOI ScienceOn |
5 | Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and manage ment. Drug Saf. 2001; 24(9): 645-663. DOI ScienceOn |
6 | Toda T, Motoki T, Kurosawa N, et al., The Relationship between dose of mycophenolate mofetil and the occurrence of cytomegalovirus infection and diarrhea in renal transplant recipients. Yakugaku Zasshi. 2005 Feb;125(2): 177-185. DOI ScienceOn |
7 | Cho E, Han D, Kim S, et al., Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol. 2004; 44: 743-750. DOI ScienceOn |
8 | Le Meur Y, Buchler M, Thierry A et al., Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007; 7: 2496-2503. DOI ScienceOn |
9 | European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet. 1995;345: 1321-1325. |
10 | Van Gelder T, Silva HT, de Fijter JW, et al., Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008 Oct 27; 86(8): 1043-51. DOI ScienceOn |
11 | The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation. 1996;61:1029-1037. DOI ScienceOn |
12 | Hale MD, Nicholls AJ, Bullingham RE, et al., The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672-83. DOI ScienceOn |
13 | Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008; 85: 1675-1685. DOI ScienceOn |
14 | Gaston RS, Kaplan B, Shah T, et al., Fixed- or controlleddose mycophenolate mofetil with standard- or reduceddose calcineurin inhibitors: the Opticept trial. Am J Transplant. 2009 Jul; 9(7): 1607-19. DOI ScienceOn |